These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2179452)

  • 21. Different pharmacological characteristics in L6 and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin.
    Pittner RA; Wolfe-Lopez D; Young AA; Beaumont K
    Br J Pharmacol; 1996 Mar; 117(5):847-52. PubMed ID: 8851500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rat amylin mediates a pressor response in the anaesthetised rat: implications for the association between hypertension and diabetes mellitus.
    Haynes JM; Hodgson WC; Cooper ME
    Diabetologia; 1997 Mar; 40(3):256-61. PubMed ID: 9084962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects on plasma glucose and lactate.
    Young A
    Adv Pharmacol; 2005; 52():193-208. PubMed ID: 16492547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance.
    Ye JM; Lim-Fraser M; Cooney GJ; Cooper GJ; Iglesias MA; Watson DG; Choong B; Kraegen EW
    Am J Physiol Endocrinol Metab; 2001 Apr; 280(4):E562-9. PubMed ID: 11254462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas.
    Inoue K; Hisatomi A; Umeda F; Nawata H
    Horm Metab Res; 1991 Sep; 23(9):407-9. PubMed ID: 1743611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of amylin on the release of insulin and glucagon from the perfused rat pancreas.
    Inoue K; Hiramatsu S; Hisatomi A; Umeda F; Nawata H
    Horm Metab Res; 1993 Mar; 25(3):135-7. PubMed ID: 8477949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amylin, amyloid and age-related disease.
    Cooper GJ; Tse CA
    Drugs Aging; 1996 Sep; 9(3):202-12. PubMed ID: 8877314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of effect of calcitonin gene-related peptide and amylin on major markers of glucose metabolism in hepatocytes.
    Pittner RA
    Eur J Pharmacol; 1997 May; 325(2-3):189-97. PubMed ID: 9163566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of the inhibitory effects of calcitonin gene-related peptide (CGRP) and amylin on insulin secretion by the 8-37 fragment of human CGRP.
    Silvestre RA; Salas M; Dégano P; Peiró E; Marco J
    Biochem Pharmacol; 1993 Jun; 45(11):2343-7. PubMed ID: 8517876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets.
    Broderick CL; Brooke GS; DiMarchi RD; Gold G
    Biochem Biophys Res Commun; 1991 Jun; 177(3):932-8. PubMed ID: 2059220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of amylin in glucose homeostasis and its perspective use in diabetes management].
    Otto-Buczkowska E; Mazur-Dworzecka U; Dworzecki T
    Przegl Lek; 2008; 65(3):135-9. PubMed ID: 18624122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of liver CGRP/amylin receptors in only nonparenchymal cells and absence of direct regulation of rat liver glucose metabolism by CGRP/amylin.
    Stephens TW; Heath WF; Hermeling RN
    Diabetes; 1991 Mar; 40(3):395-400. PubMed ID: 1847887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of amylin and calcitonin gene-related peptide on insulin-stimulated glucose transport in the diaphragm.
    Hothersall JS; Muirhead RP; Wimalawansa S
    Biochem Biophys Res Commun; 1990 Jun; 169(2):451-4. PubMed ID: 2192706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide.
    Molina JM; Cooper GJ; Leighton B; Olefsky JM
    Diabetes; 1990 Feb; 39(2):260-5. PubMed ID: 2227135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amylin-mediated reduction in insulin sensitivity corresponds to reduced insulin receptor kinase activity in the rat in vivo.
    Bryer-Ash M; Follett L; Hodges N; Wimalawansa S
    Metabolism; 1995 Jun; 44(6):705-11. PubMed ID: 7783653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-response for glucagonostatic effect of amylin in rats.
    Gedulin BR; Rink TJ; Young AA
    Metabolism; 1997 Jan; 46(1):67-70. PubMed ID: 9005972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes.
    Mäkimattila S; Fineman MS; Yki-Järvinen H
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2822-7. PubMed ID: 10946889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity.
    Mather KJ; Paradisi G; Leaming R; Hook G; Steinberg HO; Fineberg N; Hanley R; Baron AD
    Diabetes Metab Res Rev; 2002; 18(2):118-26. PubMed ID: 11994903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amylin stimulates plasma renin concentration in humans.
    Cooper ME; McNally PG; Phillips PA; Johnston CI
    Hypertension; 1995 Sep; 26(3):460-4. PubMed ID: 7649582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failure of islet amyloid polypeptide to inhibit basal and glucose-stimulated insulin secretion in model experiments in mice and rats.
    Pettersson M; Ahrén B
    Acta Physiol Scand; 1990 Mar; 138(3):389-94. PubMed ID: 2183542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.